Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treosulfan, Fludarabine and TBI Conditioning for Allo-HCT in AML, MDS, and ALL
NCT00860574Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2009
- Primary completion
- Feb 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of treosulfan in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML), sponsored by Fred Hutchinson Cancer Center. Started Feb 2009; status: completed.
02
Drugs
treosulfan
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00860574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00860574.